Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Stumvoll

Showing results (1-10 of 551) with videos related to

Pageof 56
Sort By:
Expert Opinion on Investigational Drugs|July 2, 2003
Thiazolidinediones -- some recent developmentsMichael Stumvoll
Obesity Research|November 14, 2002
Resistin and adiponectin--of mice and menMichael Stumvoll, Hans Häring
Lancet (London, England)|October 9, 2018
Twice the benefits with twincretins?Michael Stumvoll, Matthias Tschöp
Diabetes|July 30, 2002
The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphismMichael Stumvoll, Hans Häring
Diabetologia|February 15, 2002
Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2?Michael Stumvoll, H Häring
Best Practice & Research. Clinical Endocrinology & Metabolism|November 29, 2005
Fatty acids and insulin resistance in muscle and liverPeter Kovacs, Michael Stumvoll
Current Opinion in Clinical Nutrition and Metabolic Care|June 15, 2007
The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes riskAnke Tönjes, Michael Stumvoll
Diabetes Care|January 20, 2022
The Brains Behind SGLT2 InhibitionHaiko Schlögl, Michael Stumvoll
Annals of Medicine|August 14, 2002
Glitazones: clinical effects and molecular mechanismsMichael Stumvoll, Hans-Ulrich Häring
Expert Review of Endocrinology & Metabolism|February 14, 2019
ADOPT: evidence for early use of thiazolidinedionesFranziska Philomena Busse, Michael Stumvoll
Pageof 56

Showing results (1-10 of 551) with videos related to

Sort By:
Pageof 56
Expert Opinion on Investigational Drugs|July 2, 2003
Thiazolidinediones -- some recent developmentsMichael Stumvoll
Obesity Research|November 14, 2002
Resistin and adiponectin--of mice and menMichael Stumvoll, Hans Häring
Lancet (London, England)|October 9, 2018
Twice the benefits with twincretins?Michael Stumvoll, Matthias Tschöp
Diabetes|July 30, 2002
The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphismMichael Stumvoll, Hans Häring
Diabetologia|February 15, 2002
Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2?Michael Stumvoll, H Häring
Best Practice & Research. Clinical Endocrinology & Metabolism|November 29, 2005
Fatty acids and insulin resistance in muscle and liverPeter Kovacs, Michael Stumvoll
Current Opinion in Clinical Nutrition and Metabolic Care|June 15, 2007
The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes riskAnke Tönjes, Michael Stumvoll
Diabetes Care|January 20, 2022
The Brains Behind SGLT2 InhibitionHaiko Schlögl, Michael Stumvoll
Annals of Medicine|August 14, 2002
Glitazones: clinical effects and molecular mechanismsMichael Stumvoll, Hans-Ulrich Häring
Expert Review of Endocrinology & Metabolism|February 14, 2019
ADOPT: evidence for early use of thiazolidinedionesFranziska Philomena Busse, Michael Stumvoll
Pageof 56